Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis.

Lebwohl M, Langley RG, Zhu Y, Zhou H, Song M, Shen YK, Parnell Lafferty K, Reich K.

J Eur Acad Dermatol Venereol. 2019 May 11. doi: 10.1111/jdv.15668. [Epub ahead of print]

PMID:
31077471
2.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G.

J Eur Acad Dermatol Venereol. 2019 Apr 22. doi: 10.1111/jdv.15637. [Epub ahead of print]

PMID:
31009130
3.

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.

Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R.

Br J Dermatol. 2019 Feb;180(2):306-314. doi: 10.1111/bjd.17318. Epub 2018 Dec 27.

PMID:
30328108
4.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):333-339. doi: 10.1111/jdv.15242. Epub 2018 Nov 22.

PMID:
30198588
5.

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos WC.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2126-2133. doi: 10.1111/jdv.15203. Epub 2018 Aug 28.

PMID:
30067882
6.

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.

Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J Jr.

Br J Dermatol. 2018 Nov;179(5):1205-1207. doi: 10.1111/bjd.16901. Epub 2018 Sep 11. No abstract available.

PMID:
29927479
7.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23.

PMID:
29488226
8.

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).

Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P; of the IXORA-P Investigators.

Br J Dermatol. 2018 Jun;178(6):1315-1323. doi: 10.1111/bjd.16426. Epub 2018 May 15.

PMID:
29405255
9.

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. Review.

PMID:
29332708
10.

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.

Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, Meng X, Guana A, Nyirady J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):17-32. doi: 10.1007/s13555-017-0211-4. Epub 2017 Dec 7.

11.

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.

Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, Schacht A, Mallbris L, Nast A.

Br J Dermatol. 2018 May;178(5):1064-1071. doi: 10.1111/bjd.16140. Epub 2018 Mar 1.

PMID:
29171861
12.

Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.

Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, Gibbs J, Gibbs M, Kricorian G, Paller AS.

J Clin Pharmacol. 2018 Mar;58(3):340-346. doi: 10.1002/jcph.1029. Epub 2017 Nov 6.

PMID:
29106714
13.

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A.

J Am Acad Dermatol. 2018 Jan;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051. Epub 2017 Nov 6.

14.

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, Safi J Jr, Papavassilis C.

Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22. No abstract available.

PMID:
28991372
15.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.

Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, Goyal K, Langholff W, Fakharzadeh S, Srivastava B, Langley RG.

J Am Acad Dermatol. 2017 Nov;77(5):845-854.e5. doi: 10.1016/j.jaad.2017.07.013. Epub 2017 Sep 8.

16.

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.

Langley RGB, Reich K, Papavassilis C, Fox T, Gong Y, Gu Ttner A.

J Drugs Dermatol. 2017 Aug 1;16(8):734-741.

PMID:
28809988
17.

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L.

Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.

PMID:
28635018
18.

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.

Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB.

Br J Dermatol. 2017 Sep;177(3):879-881. doi: 10.1111/bjd.15656. Epub 2017 Aug 9. No abstract available.

PMID:
28498514
19.

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).

Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686-1692. doi: 10.1111/jdv.14237. Epub 2017 Apr 26.

PMID:
28322474
20.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS.

J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24. Erratum in: J Am Acad Dermatol. 2017 Aug;77(2):390-390.e1.

21.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.

Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G.

Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.

PMID:
27518376
22.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group.

N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.

23.

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A.

Br J Dermatol. 2016 Aug;175(2):273-86. doi: 10.1111/bjd.14493. Epub 2016 Jun 23.

PMID:
26914406
24.

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S.

J Am Acad Dermatol. 2016 May;74(5):841-50. doi: 10.1016/j.jaad.2016.01.013. Epub 2016 Feb 19.

25.

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, Collier DH, Kricorian G, Langley RG.

J Am Acad Dermatol. 2016 Feb;74(2):280-7.e1-3. doi: 10.1016/j.jaad.2015.09.056.

26.

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.

N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824.

27.

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S.

J Drugs Dermatol. 2015 Aug;14(8):821-33.

PMID:
26267726
28.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE.

J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049.

29.

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R.

Br J Dermatol. 2015 Oct;173(4):930-9. doi: 10.1111/bjd.13932. Epub 2015 Oct 15. Erratum in: Br J Dermatol. 2016 Jun;174(6):1426.

PMID:
26042589
30.

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.

van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl MG.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10. doi: 10.1111/jdv.13150. Epub 2015 Apr 16.

31.

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.

Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, Zhu B, Wei H, Cameron GS, Heffernan MP.

J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1763-70. doi: 10.1111/jdv.12996. Epub 2015 Feb 18.

PMID:
25693783
32.

Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

Gottlieb AB, Kalb RE, Langley RG, Krueger GG, de Jong EM, Guenther L, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Menter A.

J Drugs Dermatol. 2014 Dec;13(12):1441-8.

PMID:
25607786
33.

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators.

Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22.

34.

Qualifying unmet needs and improving standards of care in psoriatic arthritis.

Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, Kavanaugh A, Strand V, Mease PJ, Boehncke WH, Langley RG, Lubrano E, Maccarone M, Schulze-Koops H, Miceli-Richard C, Queiro R.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1759-66. doi: 10.1002/acr.22404. Review. No abstract available.

35.

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group.

N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.

36.

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC.

J Am Acad Dermatol. 2014 May;70(5):871-81.e1-30. doi: 10.1016/j.jaad.2013.12.018. Epub 2014 Feb 24.

PMID:
24576585
37.

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.

Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C.

J Dermatolog Treat. 2015 Feb;26(1):23-31. doi: 10.3109/09546634.2013.865009. Epub 2013 Dec 20. Review.

PMID:
24354461
38.

Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.

Bissonnette R, Nigen S, Langley RG, Lynde CW, Tan J, Fuentes-Duculan J, Krueger JG.

J Eur Acad Dermatol Venereol. 2014 Oct;28(10):1298-305. doi: 10.1111/jdv.12272. Epub 2013 Sep 24.

PMID:
24112799
39.

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P.

J Drugs Dermatol. 2013 Oct;12(10):1122-9.

PMID:
24085047
40.
41.

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K.

Br J Dermatol. 2013 Nov;169(5):992-9. doi: 10.1111/bjd.12517.

PMID:
23855761
42.

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.

Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):882-90. doi: 10.1111/jdv.12198. Epub 2013 Jun 22.

43.

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B.

J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61. doi: 10.1111/j.1468-3083.2012.04705.x. Epub 2012 Nov 16.

PMID:
23157612
44.

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.

Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18.

PMID:
23106107
45.

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA.

Br J Dermatol. 2012 Sep;167(3):668-77. doi: 10.1111/j.1365-2133.2012.11168.x.

PMID:
22924949
46.

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.

Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29.

PMID:
22748702
47.

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G.

Br J Dermatol. 2012 Sep;167(3):649-57. doi: 10.1111/j.1365-2133.2012.11015.x.

48.

Dermacase. Can you identify this condition? Secondary syphilis.

Webb AN, Langley RG, Hatchette TF.

Can Fam Physician. 2012 Apr;58(4):409-11. No abstract available.

49.

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

Langley RG.

J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:21-9. doi: 10.1111/j.1468-3083.2011.04412.x. Review.

PMID:
22356632
50.

Exploring new concepts in the successful management of psoriasis.

Langley RG.

J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:1-2. doi: 10.1111/j.1468-3083.2011.04409.x. No abstract available.

PMID:
22356629

Supplemental Content

Loading ...
Support Center